NASDAQ
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Sympo...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New Yor...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Fol...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025. Revenue grew 84.7% yea...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Roge...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earni...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeut...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncolog...
No price data available for this timeframe.